In-process research and development, net of accumulated amortization
69,385,938
71,106,250
72,826,562
73,400,000
Deferred financing costs
-
169,252
-
-
Total other assets
-
71,275,502
72,826,562
73,400,000
Total assets
112,093,103
100,699,168
109,973,406
100,942,881
Accounts payable
7,315,516
8,883,239
10,446,900
13,234,684
License payable
15,650,000
17,650,000
18,250,000
22,650,000
Accrued expenses
25,836,120
24,057,573
4,518,916
4,093,124
Due to related party
9,985,558
8,221,486
11,494,578
9,513,771
Total current liabilities
58,787,194
58,812,298
44,710,394
49,491,579
Notes payable, net of deferred financing costs
6,410,161
-
-
-
Deferred tax liability
2,710,643
2,817,990
3,049,200
2,784,960
Note payable to related party-Related Party
-
-
3,800,111
3,800,111
Note payable to related party
3,800,111
3,800,111
-
-
Total liabilities
71,708,109
65,430,399
51,559,705
56,076,650
Common stock - 0.0001 par value 400,000,000 shares authorized at june 30, 2026 and september 30, 2025 105,758,982 and 83,513,442 shares issued and outstanding at june 30, 2026 and september 30, 2025, respectively
10,576
9,298
8,480
8,351
Additional paid-in capital
145,481,984
131,443,191
127,979,246
108,897,836
Accumulated deficit
-105,107,566
-96,183,720
-69,574,025
-64,039,956
Total stockholders equity
40,384,994
35,268,769
58,413,701
44,866,231
Total liabilities and stockholders equity
112,093,103
100,699,168
109,973,406
100,942,881
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.